A
Amy C. Justice
Researcher at Yale University
Publications - 640
Citations - 42300
Amy C. Justice is an academic researcher from Yale University. The author has contributed to research in topics: Cohort study & Cohort. The author has an hindex of 96, co-authored 561 publications receiving 36670 citations. Previous affiliations of Amy C. Justice include University of California, Los Angeles & University Hospitals of Cleveland.
Papers
More filters
Journal ArticleDOI
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
Matthias Egger,Margaret T May,Geneviève Chêne,Andrew N. Phillips,Bruno Ledergerber,François Dabis,Dominique Costagliola,Antonella d'Arminio Monforte,Frank de Wolf,Peter Reiss,Jens D Lundgren,Amy C. Justice,Schlomo Staszewski,Catherine Leport,Robert S. Hogg,Caroline A. Sabin,M. John Gill,Bernd Salzberger,Jonathan A C Sterne +18 more
TL;DR: The CD4 cell count at initiation was the dominant prognostic factor in patients starting HAART, and should be taken into account in future treatment guidelines.
Journal ArticleDOI
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies
Robert S. Hogg,Viviane D. Lima,Jonathan A C Sterne,Sophie Grabar,Manuel Battegay,M. Bonarek,A d'Arminio Monforte,Anna Esteve,Michael Gill,RJ Harris,Amy C. Justice,A. Hayden,F Lampe,Amanda Mocroft,Jan-Christian Wasmuth,Michael J. Mugavero,S Staszewski,A.I. van Sighem,Mari M. Kitahata,Jodie L. Guest,M Egger,Margaret T May +21 more
TL;DR: Life expectancy in HIV-infected patients treated with combination antiretroviral therapy increased between 1996 and 2005, although there is considerable variability between subgroups of patients.
Journal ArticleDOI
Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada.
Hasina Samji,Angela Cescon,Robert S. Hogg,Robert S. Hogg,Sharada P. Modur,Keri N. Althoff,Kate Buchacz,Ann N. Burchell,Mardge H. Cohen,Kelly A. Gebo,M. John Gill,Amy C. Justice,Gregory D. Kirk,Marina B. Klein,P. Todd Korthuis,Jeffrey N. Martin,Sonia Napravnik,Sean B. Rourke,Timothy R. Sterling,Michael J. Silverberg,Stephen G. Deeks,Lisa P. Jacobson,Ronald J. Bosch,Mari M. Kitahata,James J. Goedert,Richard D. Moore,Stephen J. Gange +26 more
TL;DR: A 20-year-old HIV-positive adult on ART in the U.S. or Canada is expected to live into their early 70 s, a life expectancy approaching that of the general population.
Antiretroviral therapy cohort collaboration : life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies
Robert S. Hogg,Viviane D. Lima,Jonathan A C Sterne,Sophie Grabar,Manuel Battegay,M. Bonarek,A d'Arminio Monforte,Anna Esteve,Michael Gill,RJ Harris,Amy C. Justice,A. Hayden,F Lampe,Amanda Mocroft,Michael J. Mugavero,S Staszewski,Jan-Christian Wasmuth,A.I. van Sighem,Mari M. Kitahata,Jodie L. Guest,M Egger,Margaret T May +21 more
TL;DR: In this article, the authors compared changes in mortality and life expectancy among HIV-positive individuals on combination antiretroviral therapy in 1996-99, 2000-02, and 2003-05, and stratified by sex, baseline CD4 cell count, and history of injecting drug use.
Journal ArticleDOI
Effect of early versus deferred antiretroviral therapy for HIV on survival.
Mari M. Kitahata,Stephen J. Gange,Alison G. Abraham,Barry Merriman,Michael S. Saag,Amy C. Justice,Robert S. Hogg,Steven G. Deeks,Joseph J. Eron,John T. Brooks,Sean B. Rourke,M. John Gill,Ronald J. Bosch,Jeffrey N. Martin,Marina B. Klein,Lisa P. Jacobson,Benigno Rodriguez,Timothy R. Sterling,Gregory D. Kirk,Sonia Napravnik,Anita Rachlis,Liviana Calzavara,Michael A. Horberg,Michael J. Silverberg,Kelly A. Gebo,James J. Goedert,Constance A. Benson,Ann C. Collier,Stephen E. Van Rompaey,Heidi M. Crane,Rosemary G. McKaig,Bryan Lau,Aimee M. Freeman,Richard D. Moore +33 more
TL;DR: The early initiation of antiretroviral therapy before the CD4+ count fell below two prespecified thresholds significantly improved survival, as compared with deferred therapy.